Study of Impact app for advanced melanoma patients on immunotherapy
Part of Cancer, Immune system & allergy clinical trials.
This trial is testing whether a digital tool called Impact can help support patients with advanced melanoma who are receiving immunotherapy drugs like Nivolumab, alone or in combination. The goal is to see if the app helps manage treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage III (unresectable) or stage IV cutaneous melanoma that has spread.
- Your doctor must plan to treat you with Nivolumab alone or Nivolumab plus another immunotherapy (like Ipilimumab or Relatlimab), based on your PD-L1 levels.
- You must have tumors that can be measured on scans (CT or MRI).
- You must be in fairly good health (ECOG score 0 or 1), meaning you can do most daily activities.
- You must not have had prior treatment for advanced melanoma (except certain radiotherapy finished at least 2 weeks ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial tests a program that helps melanoma patients starting immunotherapy track their side effects and get faster access to specialists. The goal is to improve symptom management.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
Hear when a new Locally Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.